NCT03719118View on ClinicalTrials.gov

Tailored Therapeutic Model According to the Expression of Genes in Inflammatory Bowel Disease Patients

NACompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

October 5, 2018

Conditions
Inflammatory Bowel Diseases
Interventions
GENETIC

genotyping for three genes (TPMT, NUDT15 and FTO)

Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines

OTHER

non-genotyping

Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.

Trial Locations (5)

03722

Severance Hospital, Seoul

Unknown

Ewha Medical Research Institute, Seoul

Gangnam Severance Hospital, Seoul

Korea University Hospital, Seoul

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03719118 - Tailored Therapeutic Model According to the Expression of Genes in Inflammatory Bowel Disease Patients | Biotech Hunter | Biotech Hunter